Nga paanga o te ginsenosides ki nga cytokines i roto i te fibrosis okana
Ko te TGF- 1 he cytokine mahi maha me nga ahuatanga fibrosis, he mea nui ki te fibrosis okana. Ka whakatairangahia te fibrosis okana ma te whakatere i te whakahekenga o te ECM me te whakaiti i tona paheketanga. Ko Smad tetahi take whakawhiti tohu nui i roto i te TGF{3}}whakaaro tohu. I tua atu, ka whai waahi nui te whakaheke ECM ki te whakawhanaketanga o te fibrosis pulmonary. Ko te ECM te nuinga i whakahekehia e te MMP, a, ko te kaha o te whakahekenga o te MMP i te nuinga o te waa i whakahaeretia e nga kaiwawao MMP. Ko te taurite i waenga i te MMP me te aukati kiko o te metalloproteinase (TIMP) ka whai waahi nui ki te hanga o te fibrosis okana.
I roto i te tauira o te cCL4-te fibrosis ate, ko nga metabolite paitini o CCl4 ka whakahohe i nga pūtau Kupffer ki te huna i nga cytokines, penei i te IL-1 me te TNF-, me te whakaihiihi i te hanga o TGF- . Hou et al. i kitea ko te ginsenoside Rb1 i aukati i te fibrosis ate ma te whakaheke i nga taumata o te TNF-, Prostaglandin E2 (PGE2) me te TIMP-1 i roto i te ate.
Guan et al. i kitea ka taea e te ginsenoside Rg1 te whakaiti i te pūmua me te mRNA whakaaturanga o TGF - 1, Smad 2 me Smad 3 i roto i te kiore fibrosis pūkahukahu, me te tino whakarei ake i te whakapuakitanga o Smad 7. Ko enei hua e tohu ana ka taea e ginsenosides te aukati i te fibrosis pulmonary na roto i te aukati i te TGF - 1/Smad te arai tohu deliferation. Yang et al. i kitea ka taea e nga ginsenosides katoa te whakaheke ake i te -ture o MMP2, MMP9 me TIMP-1 whakaaturanga pūmua i roto i nga kiore pulmonary fibrosis, me te paanga whakamarumaru ki te bleomycin (BLM) -induced pulmonary fibrosis e pa ana ki te punaha MMP. Ko te mahi matua a TIMP-1 ko te whakahaere i nga mahi huna me nga mahi a te MMP, a ka tino piki ake tona whakaaturanga me te piki haere o te fibrosis pulmonary. Ko te korero o te MMP2 me te MMP9 ka whakanuihia i te wa o te waahi o te mumura o te BLM-induced pulmonary fibrosis, ka whai waahi pea ki te whakangaro i te membrane o raro, te whakaekenga o te waahi alveolar e te fibroblasts, me te fibrosis pulmonary.
Xu et al. i kitea ka taea e te ginsenoside Rg1 te aukati i te hangahanga autophagosome me te roha reticulum endoplasmic. Ka whakatauritea ki te roopu adriamycin, ka whakahohehia e te roopu ginsenoside Rg1 te tauwehe whakamaoritanga 6 ( ATF6, inositol -e hiahia ana i te enzyme 1 (IRE1), tauwehe takawaenga transcriptional1, Phosphorylated Ribosomal protein S6 kinase, phosphorylated Ribosomal protein S6 kinase}}} P{{71J{71}}} N{17}}kinase 1, JNK1 me Beclin1, pūmua ture glucose 78 (GRP78) i whakanuia e enei hua ka taea e te ginsenoside Rg1 te whakapai ake i te doxorubicin{25}}i te ngoikoretanga o te ngakau ma te aukati i te ahotea o te reticulum endoplasmic me te GTP binding e kitea ana te GTP binding pūmua, Rho -porowhita whai -coil hanga kinase pūmua (RHO-coil related-coil forming protein kinase, rho-rere related coil -coil forming protein kinase ROCK (ROCK) me te PI3K/ mammalian Ko nga ara o te rapamycin (mTOR) ka aukati i te autophagy o nga cardiomyocytes kiore ki te purei i te mahi anti-he ngoikore o te ngakau I tua atu, ka taea e te ginsenoside Re te whakaiti i nga hua o te TGF{42}}} o te pharaora o te toto me te whakapai ake i te whakakitenga o te pharroprotein4. myocardial fibrosis me te ngoikore o te ngakau (he iti rawa tetahi waahanga) na roto i te whakaputanga o te Smad 3 me te momo I collagen i roto i te kiko ngakau, e hono ana ki te whakaritenga o te ara TGF - 1/Smad 3.
Li et al. i kitea ka taea e te UUO te whakatairanga i te whakahuatanga o te TGF- 1 me te phosphorylated Smad 3 (P-smad 3) me te aukati i te whakahuatanga o Klotho (KL) me Smad 7, a ka hurihia enei korero i muri i te whakahaerenga o te ginsenoside Rg1. Ko nga hua e kii ana ko te ginsenoside Rg1 e whakatika ana i te renal tubulointerstitial fibrosis ma te aro ki te ara Klotho/TGF - 1/Smad, a ko tenei tauira whakamarumaru e tautoko ana i te whakamahi ginsenoside Rg1 ki te rongoa i te renal fibrosis e pa ana ki te ngoikoretanga o Klotho. Zhou et al. i whakapumau i te tauira kiore mate huka ma te whangai i te -te huka me te nui{14}}te kai ngako me te STREptozotocin IP. Ko nga rereketanga o te hyperglycemia ka kino pea nga pūtau mesangial me te whakatairanga i te apoptosis, engari ko te whakaheke i te whakawhitinga lipid me te whakahekenga lipid rereke ka arahi ki te hyperplasia o te membrane pūtau glomerular me te whakaemi haere o te ECM. I kitea ko te 20(S) -ginsenoside Rg3 i tino heke-i te whakaputanga o te TGF- 1, NF-κB P65 me TNF- i roto i nga whatukuhu. Ko nga hua e whakaatu ana ka taea te whakamahi 20(S) -ginsenoside Rg3 ki te maimoatanga o te nephropathy mate huka ki tetahi huarahi hou.
Ko te Fibrosis he ahua noa o te maha o nga mate okana-i whaaia, engari karekau he rongoa rongoa pai i naianei, a, ko te kitenga o nga puhui mata me te tino pai, te iti o te paitini, me te mahi anti-fibrosis he tino matea haumanu. He maha nga paanga rongoa a Ginsenosides, penei i te antioxidant, anti-inflammatory, pro-apoptotic and immune stimulation, me era atu. Kua whakauhia tona hua anti-fibrosis, engari kei te noho marama tonu te tikanga o raro. Ko te tikanga motuhake o te ginsenoside anti-fibrosis me arotake ano.
I arotakehia te saponin ginseng i roto i tenei pepa mo te tikanga anti-fibrosis, tae atu ki te EMT te aukati i te tauhohenga mumura me te aukati i te pūtau, te whakapai ake i te ahotea oxidative, te aukati i te hanga collagen, te whakarite korero cytokine, me era atu, mo te ako i te tikanga o te anti-fibrosis o te kitenga o nga pūhui mata me te whakarato i te fibrosis o te ginseno rongoa, mo te fibrosis o te ginsenina rongoa. Ko te rangahau he kaupapa ariā.
